OncoMatch/Clinical Trials/NCT06886347
Metastatic Nasopharyngeal Carcinoma
Is NCT06886347 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Penplimab and Antitinib Hydrochloride Capsules for metastatic nasopharyngeal carcinoma.
Treatment: Penplimab · Antitinib Hydrochloride Capsules · Gemcitabine — To evaluaate the efficacy and safety of the regimen incuding Penpulimab, Gemcitabine and Anlotinib in the treatment of metastatic nasopharyngeal carcinoma. Using Progression-Free-Survival as the primary endpoint.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage IVB
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: immunotherapy
Have previously received immunotherapy, including immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy, and other treatments against tumor immune mechanism.
Cannot have received: anti-angiogenic therapy
Previously received anti angiogenic therapy.
Cannot have received: systemic treatment for locally advanced disease
Exception: excluding oral single agent chemotherapy maintenance
Progression during or within 6 months after receiving systemic treatment for locally advanced disease (including induction therapy, concurrent radiotherapy, adjuvant therapy) (excluding oral single agent chemotherapy maintenance).
Cannot have received: secondary radiotherapy
Patients with recurrent nasopharyngeal lesions after radiotherapy and who have received secondary radiotherapy.
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06886347 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IVB is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages